Scholarlink

Purpose <p>Mutational analysis guides therapeutic decision-making for patients with advanced-stage gastrointestinal stromal tumors (GISTs).</p> Materials and methods <p>A total of 491 patients with GISTs were retrospectively included, and their genomic profiles were determined by targeted NGS of 73 or 1,021 gene panels.</p> Results <p><i>KIT</i> mutations were identified in 84.7% (416/491) of patients with GISTs, and <i>PDGFRA</i> mutations were identified in 4.5% (22/491) of patients. Among the patients with <i>KIT</i> mutant-GISTs, most had <i>KIT</i> mutations in exon 11 (81.3%, 338/416). <i>PDGFRA</i> mutations were located mainly in exon 18 (77.3%, 17/22). In the remaining 11% of patients with GISTs without <i>KIT</i> or <i>PDGFRA</i> mutations (wild-type GISTs), <i>BRAF</i> and <i>NF1</i> were the most commonly mutated genes. Compared with <i>KIT</i>/<i>PDGFRA</i>-mutant GISTs, wild-type GISTs were associated with younger age, a greater proportion of female patients, and lower levels of copy number variations. Notably, the concomitant alterations of <i>KIT</i>/<i>PDGFRA</i>-mutant or wild-type GISTs were similar when sequencing data from a 73-gene panel and a 1,021-gene panel were analyzed. The genetic landscape of patients with treatment-naïve GISTs at different locations was described by using a 73-gene panel, and compared with patients with gastric GISTs, patients with nongastric GISTs had higher levels of copy number variations but a lower proportion of <i>PDGFRA</i> mutations. Analysis of the genomic profiles before and after imatinib treatment revealed <i>KIT</i> T670I mutation, as well as <i>ATM</i> and <i>JAK2</i> mutations, as potential underlying mechanisms of resistance.</p> Conclusion <p>Using a 73-gene panel, we characterized the molecular characteristics of GISTs and revealed a correlation with their clinical features. Moreover, KIT/PDGFRA-dependent and KIT/PDGFRA-independent mechanisms underlying resistance to imatinib were explored. Overall, our 73-gene panel is sufficient for clinical application in cases of GISTs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mutational landscape of gastrointestinal stromal tumors using next-generation sequencing of a 73-gene panel

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Chang Wang,
  • Baosen Cheng,
  • Shuya Yang,
  • Huan Yin,
  • Yuanyuan Xiong,
  • Rongrong Chen,
  • Yuqing Wu,
  • Chao Wang,
  • Bo Wang,
  • Zhidong Gao,
  • Yingjiang Ye

摘要

Purpose

Mutational analysis guides therapeutic decision-making for patients with advanced-stage gastrointestinal stromal tumors (GISTs).

Materials and methods

A total of 491 patients with GISTs were retrospectively included, and their genomic profiles were determined by targeted NGS of 73 or 1,021 gene panels.

Results

KIT mutations were identified in 84.7% (416/491) of patients with GISTs, and PDGFRA mutations were identified in 4.5% (22/491) of patients. Among the patients with KIT mutant-GISTs, most had KIT mutations in exon 11 (81.3%, 338/416). PDGFRA mutations were located mainly in exon 18 (77.3%, 17/22). In the remaining 11% of patients with GISTs without KIT or PDGFRA mutations (wild-type GISTs), BRAF and NF1 were the most commonly mutated genes. Compared with KIT/PDGFRA-mutant GISTs, wild-type GISTs were associated with younger age, a greater proportion of female patients, and lower levels of copy number variations. Notably, the concomitant alterations of KIT/PDGFRA-mutant or wild-type GISTs were similar when sequencing data from a 73-gene panel and a 1,021-gene panel were analyzed. The genetic landscape of patients with treatment-naïve GISTs at different locations was described by using a 73-gene panel, and compared with patients with gastric GISTs, patients with nongastric GISTs had higher levels of copy number variations but a lower proportion of PDGFRA mutations. Analysis of the genomic profiles before and after imatinib treatment revealed KIT T670I mutation, as well as ATM and JAK2 mutations, as potential underlying mechanisms of resistance.

Conclusion

Using a 73-gene panel, we characterized the molecular characteristics of GISTs and revealed a correlation with their clinical features. Moreover, KIT/PDGFRA-dependent and KIT/PDGFRA-independent mechanisms underlying resistance to imatinib were explored. Overall, our 73-gene panel is sufficient for clinical application in cases of GISTs.